A Pharmacokinetic Study of Potassium Perfluorooctanesulfonate in the Cynomolgus Monkey Southern Research Institute Study ID: 9921.6 April 22, 2003 Final Report on A Pharmacokinetic Study of Potassium Perfluorooctanesulfonate in the Cynomolgus Monkey To: 3M Corporation P.O.

Study Title Soil Adsorption/Desorption Study o f Potassium Perfluorooctanesulfonate (PFOS) Data Requirem ent Based on OECD 106 A u th o r M ark E.

BACK TO MAIN 3M FLUOROCHEMICAL SUBMISSION TOXICOLOGY, EPIDEMIOLOGY AND MEDICAL SURVEILLANCE February 2005 Click on Study Title to View Report February 10, 2005 Geary Olsen and Larry Zobel (3M), Comments of the 3M Company to the EPA Sci ence Advisory Board PFOA Review Panel, February 10, 2005 February 10, 2005 John A.

M&S.6 _ 0637 If Charles Auer ' 05/16/2000 03:42 PM To: waweppner@mmm.com, dchakes1@mmm.com cc: Oscar Hernandez/DC/USEPA/US@EPA, Jennifer Seed/DC/USEPA/US, Barbara Leczynski/DC/USEPA/US@EPA, Karen Lannon/DC/USEPA/US@EPA Subject: PFOS items Following up on my phone call with Bill Weppner on May 15, I want to confirm a few points: 3M has arranged a discussion with the Commission of the EU on May 24 in Brussels to discuss PFOS.

NORTHERN KENTUCKY OFFICE SUITE 340 1717 DIXIE HIGHWAY COVINGTON, KENTUCKY 41011-4704 606-331-2838 513-381-2838 FAX: 513-381-6613 DAYTON, OHIO OFFICE SUITE 900 110 NORTH MAIN STREET DAYTON, OHIO 45402-1786 937-228-2838 FAX: 937-228-2816 R o b e r t a .

AZ2Z(o- tf3C> February 1, 2005 Data Validation for PFOS/PFOA Oakdale Project (MDH Sample Numbers 200501211-200501219) Sample receipt: Samples were received in good condition.

AR226-2048 / / Ta-Wei Fu 07/30/2001 08:01 AM .

AR226-2196 From: Fred M Lentz on 08/28/2001 07:54 AM To: Ta-Wei Fu/SE/DuPont@DuPont cc: Stephen J Gissy/AE/DuPont@DuPont, Oscar T Garza/AE/BuPont@DuPont, Robbin Banerjee/AE/DuPont@DuPont, Paul K Mathur/CL/DuPont@DuPont, David M Rurak/AE/DuPont@DuPont, Raymond C Butterworth/CL/DuPont@DuPont, John R Flynn/AE/DuPont@DuPont, Amy L Brown/AE/DuPont@DuPont, Thomas W Mahlberg/SE/DuPont@DuPont, Robert F Pinchot/DEV/AE/DuPont@DuPont, Chris E Shoop/AE/DuPont@DuPont, Roger J Zipfel/AE/DuPont@DuPont, Alvin H Gibson_Jr/CL/DuPont@DuPont, Debbie J Mulrooney/AE/DuPont@DuPont, Kenneth P Kelch/AE/DuPont@DuPont Subject: Re: ACTION ITEMS FROM APFO DISPERSION MODELLING D Ta-W ei If you have not already done so, please take a moment to review these results with Ken Kelch.

AR226-2216 Chris E Shoop 11/19/2001 03:08 P M _________ _______ _ To: Ralph M Aten/AE/DuPont@DuPont cc: Debbie J Mulrooney/AE/DuPont@DuPont Su bject Particulate / C -8 Em issions from Semiworks Ralph, In about August of this year 1used information from the semiworks air permit application that you were preparing to provide data to the state on total C-8 emissions for the site.

AR226-2311 Paul R Jann 03/13/2003 01:27 PM To: cc: Subject: Catherine A Barton/AE/DuPont@DuPont Wilfred K Whitcraft/AE/DuPont@DuPont, Charles J Zarzecki/AE/DuPont@DuPont, Mark C Hause/DuPont@DuPont Re: air monitoring Q Cathy, Sometimes you need a little real data to satisfy both the Agency and the public when it comes down to sensitive issue like carcinogen HAPs.

3M Katherine E.

RECEIVED irrt cno OfrJUL-5 AHII: 22 AK 2Z _ 373Z Self-Reported Medical Conditions in Perfluorooctanesulfonyl Fluoride Manufacturing Workers Final Report Bruce H.

M 2 S 6 _ 373C Andrea V.

ATSttCn:A SDeocctuiomne8n(et)P/FroYcIessing Center Attachment 1 P-1 P-1 July 28,2006 Page 4 of 5 M Z26 _373J- Acronym codefor Tables 1 and 2 In Tables 1 and 2, the following acronyms are used: acronym meaning CW FW WW DuPont Chambers Works facility in Deepwater, New Jersey DuPont Fayetteville Works facility in Fayetteville, North Carolina DuPont Washington Works facility in Parkersburg, West Virginia PPPFFFHPBeAxAA PFHpA PPPPFFFFOUDNnAAAA PFDoA PFBS PPPFFFOHOSxSSA PPeerrfflluuoorroobpuentatannooicicaacicdid Perfluorohexanoic acid Perfluoroheptanoic acid Perfluorooctanoic acid Perfluorononanoic acid Perfluorodecanoic acid Perfluorotmdecanoic acid PPPeeerrrfffllluuuooorrrooobhdueoxtdaaennceaenssuoulilfcfooanncaaitdtee Perfluorooctane sulfonate Perfluorooctane sulfonamide Attachment 1 Spaed Matrix Lab Blank 1 cw # P % cw p 3 cw n m 34 CW (DUPLICATE) c w v 5 cw i cw < P * CW 7 cw qp ( CW WG18817-102 Y2 WG18817-101 Y1 L8789-1 Y1 LB789-2 Y1 L87B9-3 Y1 WG18817-103Y1 L8789-4 Y1 L8789-5 Y1 LB789-5 Y1 LB789-6 Y1 L8789-7 Y1 L8789-8 Y1 % Recovery ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL WQ18817 W Q 18817 WQ18817 WQ18817 WG18817 WG18817 WG18817 WG18817 WG18817 WG18817 WG18817 WG18817 PFBA 81.2 ND ND ND ND ND ND <1.44 <1.44 <1.44 NO ND PFPeA 79.0 ND ND ND ND ND ND ND NO ND ND ND PFHxA 85.8 ND 1.82 ND <0.900 <0.900 ND ND ND <0.900 ND <0.900 PFHpA 83.5 ND ND ND ND ND <1.41 3.71 3.71 11.7 6.91 ND PFO A 110 ND 7.71 9.72 24.1 21.6 42.8 13.4 13.4 111 56.7 26.6 PFNA 11B ND 4.28 2.90 7.10 6.78 18.3 4.22 4.22 53.1 29.2 2.37 PFDA 115 ND <1.06 <1.08 1.64 1.51 8.47 1.82 1.82 13.5 7.47 <1.08 PFUnA 128 ND <1.02 <1.02 2.37 2.60 1.70 <1.02 <1.02 3.99 1.55 ND PFDoA 60.9 ND ND ND <0.600 <0 600 0.943 <0.600 <0.600 1.10 0.737 ND PFBS 94.8 ND ND ND ND ND ND ND ND ND ND ND PFHxS 104 ND <3.72 <3.72 39.1 33.5 <3.72 <3.72 <3.72 4.28 <3.72 3.81 PFOS 112 ND 51.1 35.3 68.2 58.0 25.7 35.0 36.0 39.0 53.8 36.8 PFO SA 73.5 ND ND ND ND ND ND ND ND NO ND ND Attachment 1 PFBA PFPeA PFHxA PFHpA PFOA PFNA PFDA PFUnA PFDoA PFBS PFHxS PFOS PFOSA tp // CW ^ k F w t f f lV L8789-9 Y1 LS789-10Y1 L8789-11 Y1 ngftnL ngAnL WG1B817 WG18817 ngAmL WG18817 ND ND NO ND ND ND ND ND ND NO 1.48 ND 12.9 13.0 28.3 <1.53 3.97 2.28 ND <1.08 <1.08 ND <1.02 <1.02 ND ND ND ND ND ND <3.72 <3.72 6.64 30.7 46.9 37.2 ND ND ND t-2.

P-1 TSCADocument Processing Center Attn: Section 8(eVFYI yf fL 7 - 7 i- 3 7 3 S Attachment 2 p- 2 July 28,2006 Page 5 of 5 Axys Analytical Services Laboratory - Form 1A and Form 2 (2 pages) P-2 P-3 s r.......... 7 ' "r *'*.".* *'"' ______;______